VISEN Pharmaceuticals
VISEN Pharmaceuticals43About
What does VISEN Pharmaceuticals do?
VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from inflammatory and fibrotic diseases. Their lead drug candidate, VISN-101, is a novel small molecule inhibitor targeting a key pathway implicated in these conditions. The company aims to address significant unmet medical needs in areas like idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders.
What is VISEN Pharmaceuticals's revenue?
StartupHub estimates VISEN Pharmaceuticals's annual revenue at $48.1M (range $10.3M to $198.4M, 29% confidence), based on comparable companies in the sector.
What is VISEN Pharmaceuticals's valuation?
StartupHub estimates VISEN Pharmaceuticals's effective valuation at $772.0M (range $500.0M to $1.2B, 18% confidence), based on comparable companies in the sector.
How much funding has VISEN Pharmaceuticals raised?
VISEN Pharmaceuticals has raised a total of $200M in funding.
Where is VISEN Pharmaceuticals headquartered?
VISEN Pharmaceuticals is headquartered in San Diego, United States.
When was VISEN Pharmaceuticals founded?
VISEN Pharmaceuticals was founded in 2017.
What industry does VISEN Pharmaceuticals operate in?
VISEN Pharmaceuticals operates in Biotech, Drug Discovery, Clinical Trials, Fibrotic Diseases, Inflammatory Diseases, MedTech.
No comments yet. Be the first to share your take.